# Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

> **NCT06077656** · PHASE2 · COMPLETED · sponsor: **Inventprise Inc.** · enrollment: 220 (actual)

## Conditions studied

- Pneumococcal Vaccines

## Interventions

- **BIOLOGICAL:** IVT PCV-25 Formulation A
- **BIOLOGICAL:** IVT PCV-25 Formulation B
- **BIOLOGICAL:** IVT PCV-25 Formulation C
- **BIOLOGICAL:** PCV 20

## Key facts

- **NCT ID:** NCT06077656
- **Lead sponsor:** Inventprise Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-25
- **Primary completion:** 2024-05-24
- **Final completion:** 2024-05-24
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2026-03-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06077656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06077656, "Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06077656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*